20% off purchase of 3 or more products* | Learn More >>

Polyclonal Antibody Axonal Fasciculation

Also showing Polyclonal Antibody Western Blotting Axonal Fasciculation

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Western Blotting

Background: Neuronal Cell Adhesion Molecule, or NRCAM, belongs to the immunoglobulins Cell Adhesion Molecules (CAM's) superfamily (1). NRCAM, an ankyrin-binding protein, contributes to the neurite outgrowth by providing directional signaling during axonal cone growth (2, 3, 4). Additionally, it plays a role in mediating the interaction between axons and Schwann cells and contributes to the formation and maintenance of Nodes of Ranvier (5, 6, 7, 8). NRCAM also plays an important role in the establishment of dendritic spines in developing cortical neurons (9). NRCAM is expressed in non-neuronal cells, mostly in endothelial cells (10).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Neurite outgrowth inhibition protein (Nogo, RTN4) is a reticulon family protein that was identified as an axonal growth inhibitor of the central nervous system (CNS). Nogo occurs as three major isoforms (Nogo-A, Nogo-B, and Nogo-C) that share a common carboxy terminus of 188 amino acids. Nogo-A is transmembrane protein enriched in the endoplasmic reticulum and expressed at high levels in the CNS, and more weakly in skeletal and heart muscle (1-3). Expression of Nogo-A decreases with increasing age during brain development. In the adult CNS, negative regulation of neuronal growth leads to stabilization of the CNS wiring at the expense of extensive plastic rearrangements. Nogo-A meditates inhibition of neurite growth together with the nogo receptor 1 (NgR1), the p75 neurotrophin receptor p75NTR, and the transmembrane LINGO1 protein. This Nogo receptor signaling complex activates the RhoA/ROCK pathway, which collapses neuronal growth cones and inhibits axonal growth in the CNS following traumatic brain injury. Research studies suggest that inhibition of Nogo A may be beneficial to patients with traumatic brain injury. Nogo-B and Nogo-C inhibit BACE1 activity and amyloid precursor protein processing, suggesting a role in cell survival (4).